Navigation Links
Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Date:8/5/2008

Investor Conference Call to be held on Wednesday, August 6, 2008 at 8:00

a.m.

EXTON, Pa., Aug. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today positive top-line efficacy and safety results from two pivotal, Phase III clinical studies (Studies IT-R-005 and IT-R-006) of the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles. Each study, conducted under an FDA Special Protocol Assessment (SPA), met all primary endpoints and was highly statistically significant, making this a major clinical milestone for the Company.

"This is a significant achievement for Isolagen and an important step towards bringing the first ever autologous cell therapy product to the market for aesthetic use. As the future evolves and current therapies continue to show their age, the need for novel skin rejuvenation products becomes evident. With these statistically significant results, we believe we are now in an excellent strategic position," said Nicholas L. Teti, Jr., Chairman of Isolagen. "These results further support the proof of principle for autologous cell therapy and open the door for further research in aesthetics, acne scars, burn scars and other clinical applications."

The pivotal, Phase III placebo-controlled studies investigating the efficacy and safety of Isolagen Therapy for the treatment of nasolabial folds, or wrinkles, evaluated a total of 421 people at 13 clinical sites across the United States. In Study IT-R-005, both the Evaluator and Patient evaluations met the co-primary endpoints and were statistically significant achieving p values of <0.0001 and 0.0001, respectively. In Study IT-R-006, statistical significance was also achieved for both primary efficacy endpoints, achieving p values of 0.0075 and <0.0001 for the Evaluator and Patient evaluations, respectively.

Top-line statistical results showed that p values at Month 6 following third injection were co
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
2. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
4. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: ... corporate presentations at two upcoming investor conferences.  , ... on Tuesday, December 2, 2014 at 6:45 a.m. EST ... and head of EUSA International, will provide an overview of the ... Annual Piper Jaffray Healthcare Conference in New York, ...
(Date:11/26/2014)... Nov. 26, 2014 China Nepstar Chain Drugstore ... a leading retail drugstore chain in China based on ... unaudited financial results for the third quarter ended September 30, ... 2014: , Same store sales increased by 8.1% ... Revenue increased by 8.1% to RMB738.3 million (US$120.3 million) compared ...
(Date:11/24/2014)... , Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. ... conducted in Melbourne, Australia ... the potential treatment of paroxysmal supraventricular tachycardia (PSVT).  ... MSP-2017 was well tolerated at single doses up ... safety profile, desirable PK properties including rapid onset, ...
Breaking Medicine Technology:Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/24/2014)... From embedded sensors and biometrics to elite ... will take center stage at the FitnessTech Summit , ... 2015 International CES® , January 6, 2015 in Las ... 2004). The bond between fitness and technology is stronger than ... and more about the human body. , “Fitness technology has ...
(Date:11/24/2014)... Abington, PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology ... Abington Health’s Multiple Sclerosis Center. , A graduate ... residency in Neurology at Albert Einstein Medical Center in ... the Judith Jaffe Multiple Sclerosis Center at Weill Cornell ...
(Date:11/24/2014)... 24, 2014 The Holiday Inn Westbury ... Family and Children's Association to donate various items ... mouthwash and other such items.The Association's program is aimed ... bound, living in nursing homes, assisted living facilities and ... the well being of seniors throughout the Long Island ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 ReAdmission ... and disease management services to health plans, hospitals, ... Essette’s Medical Management software suite. ReAdmission Solutions ... in a program to reduce patients' avoidable readmissions ... Health Management, Care Management, Utilization Management, and Appeals ...
Breaking Medicine News(10 mins):Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2
... AIGISRx DEB is designed to reduce the severity of capsular ... ... capsule formation, MONMOUTH ... the commercialization of implantable medical-pharmaceutical,devices, announced today acceptance for presentation ...
... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based,medical ... intensity focused ultrasound tumor,therapy systems, today announced the following investor events: Event ... ... Location UBS China Life ...
... critically needed supplies to ... clinics, fire and rescue in affected areas, SANTA ... emergency medical supplies to safety-net,clinics and has extended offers ... fires have forced 500,000 people to,evacuate their homes. ...
... Inc announced today that its,La Jolla campus will close ... to cope with San Diego County,s ongoing fire,emergency. Determination ... from the many agencies involved in dealing with the,disaster. ... by the fires so it,s,important that they take the ...
... Research and,Manufacturers of America (PhRMA) President and CEO ... wildfires: "Californians who have been affected by ... underinsured -- should know that help getting the,medicines ... for,Prescription Assistance. The PPA, sponsored by America,s pharmaceutical,research ...
... Department of,Veterans Affairs (VA) continues to offer medical care ... across parts of Southern,California., "We are grateful no ... Secretary of Veterans Affairs Gordon H. Mansfield.,"Our first priority ... The San Diego VA Medical Center and clinics remain ...
Cached Medicine News:Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 2Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 3Health News:China Medical Technologies to Participate in Investor Events in November 2Health News:Direct Relief International Aims California Fire Response at Health Concerns 2Health News:Help for California Fire Evacuees Possible Through Partnership for Prescription Assistance 2
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... It is designed for ... the surgeon greater freedom in ... 3-point rigid skeletal fixation is ... lateral, or sitting positions. Craniotomies ...
Medicine Products: